2017年全球瘙痒症治疗性市场估计为10,6752.1百万美元,预计将在未来几年内获得大量牵引力。
Pruritus是一种慢性瘙痒症,由于皮肤病,例如接触皮炎,水痘,岩霉素和特应性皮炎等皮肤病。此外,瘙痒症具有许多基本的病因,例如尿道瘙痒结果来自透析和慢性肾疾病,肝源瘙痒结果来自黄疸和肝炎,有些形式是药物产生的瘙痒。瘙痒症是在真皮组织中的自由神经结束的刺激的结果,其通过C纤维转移并通过位于脊髓中的纺丝素散流。这种程序标志着瘙痒的形式。随后,该疾病是胆汁淤积,全身感染,恶性肿瘤,慢性肾功能衰竭,内分泌障碍和神经系统紊乱和或暴露于几种药物的指示。国际速度研究国际论坛(IFSI)估计了三种类型的瘙痒症,慢性次要划痕病变,正常皮肤上的瘙痒或发炎皮肤。慢性瘙痒的许多个体在缺乏皮肤病的缺乏皮肤病中具有皮肤伤口,这主要是由于皮肤干燥,刮擦或昆虫咬伤。此后,IFSI的这种分类有助于在疾病诱导和非特异性疾病诱导的瘙痒症中产生明显的差异。瘙痒症诊断需要彻底分析,涉及实验室调查和临床检查,通常是心动,皮肤病,神经源性和全身性的。
全球瘙痒症治疗性市场主要是由于对柜台上常规(OTC)局部皮质类固醇的需求不断增加。此外,Pruritus治疗和新产品介绍的强管道是促进瘙痒治疗市场的另一个关键因素。鉴定新的T细胞亚群,如Th17和Th22和许多瘙痒治疗药物如癌症(Tacrolimus)的专利到期,是预计推动市场增长的另一个因素。此外,瘙痒症涵盖了各种潜在的靶人群,因为皮肤病是一个非常普遍的全世界问题。这些因素将为新的关键参与者提供进入的进入区域,以便形成有利于预测期间瘙痒治疗市场的增长的利润丰厚的机会。
然而,缺乏定位瘙痒的起源的意识是预计妨碍市场瘙痒症的主要因素之一。
全球瘙痒症治疗性市场是在产品,疾病类型和地理的基础上进行分割。
在产品的基础上,全球瘙痒治疗性市场被分段为皮质类固醇,抗组胺药,局部麻醉剂,发泡剂,免疫抑制剂,钙塞蛋白抑制剂等。2017年,皮质类固醇预计将通过产品段主导市场,因为皮质类固醇被广泛用作第一线治疗。在疾病类型的基础上,全球瘙痒治疗性市场被分段为特应性皮炎,过敏性接触皮炎,荨麻疹等。2017年,估计过敏性接触性皮炎占据了市场部门。这是3rd.most general cause for patients seeking consultation with a dermatology specialist. Allergic contact dermatitis is commonly observed in women.
就地理位置而言,北美估计to dominate the global pruritus therapeutics market. The dominance is majorly due to The presence of favorable government initiatives and the introduction of new products. Moreover, rising incidence of target disorders and the existence of pruritus inducing climatic disorders in this region are anticipated to boost the market growth during the forecast period. However, Asia Pacific is anticipated to dominate the global Pruritus Therapeutics Market. Growing incidence of atopic dermatitis and urticarial and presence of unmet healthcare organization needs are the factors attributed to the growth of the market in the Asia Pacific.
Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Pruritus Therapeutics Market includes Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others.